Financials Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:09 2024-06-24 am EDT 5-day change 1st Jan Change
12.75 GBX +4.94% Intraday chart for Poolbeg Pharma PLC -8.27% +40.88%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 47.5 30.25 45.25 63.75 -
Enterprise Value (EV) 1 47.5 14.06 33.08 57.55 63.25
P/E ratio -12.8 x -6.44 x -11.5 x -9.81 x -10.6 x
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA - -2.83 x -7.1 x -8.85 x -10.2 x
EV / FCF - -2.83 x -7.26 x -9.75 x -11.1 x
FCF Yield - -35.3% -13.8% -10.3% -9.01%
Price to Book - 1.65 x 3.02 x 7.97 x 31.9 x
Nbr of stocks (in thousands) 500,000 500,000 500,000 500,000 -
Reference price 2 0.0950 0.0605 0.0905 0.1275 0.1275
Announcement Date 3/2/22 3/30/23 4/30/24 - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - - - - -
EBITDA 1 - -4.96 -4.66 -6.5 -6.2
EBIT 1 - -4.986 -4.686 -6.528 -6.285
Operating Margin - - - - -
Earnings before Tax (EBT) 1 - -4.777 -4.505 -6.375 -6.235
Net income 1 -2.336 -4.686 -3.931 -6.375 -6.235
Net margin - - - - -
EPS 2 -0.007400 -0.009400 -0.007900 -0.0130 -0.0120
Free Cash Flow 1 - -4.965 -4.556 -5.9 -5.7
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/2/22 3/30/23 4/30/24 - -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt 1 - - - - -
Net Cash position 1 - 16.2 12.2 6.2 0.5
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - -4.97 -4.56 -5.9 -5.7
ROE (net income / shareholders' equity) - -22.9% -24% -77.6% -318%
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share 2 - 0.0400 0.0300 0.0200 0
Cash Flow per Share - - - - -
Capex 1 - 0.6 0.18 0.1 0.1
Capex / Sales - - - - -
Announcement Date 3/2/22 3/30/23 4/30/24 - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1275 GBP
Average target price
0.21 GBP
Spread / Average Target
+64.71%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. POLB Stock
  4. Financials Poolbeg Pharma PLC